Clinical trial
Growth Hormone Resistance of Beta-cells A
Recruiting now · Not applicable · 1 countries · Registry ID NCT06571487
Recruiting nowNot applicableObservational
What this study is about
The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 45 Years
SexFemale
Healthy volunteersAccepted
ConditionGestational Diabetes, Obesity, Healthy
Full registry criteria
Inclusion Criteria: * Singleton, full term pregnancy within the past 5 years * Body mass index ≥18.5 kg/m2 and \<45.0 kg/m2 Group specific inclusion criteria: * Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy * Control Group: no history of gestational diabetes Exclusion Criteria: * Pregnant, planning to become pregnant during the study, or breastfeeding * Current diagnosis or history of type 1 or type 2 diabetes * Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists) * History of bariatric surgery * Known, uncontrolled hypothyroidism * History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment * Current cancer or cancer that has been in remission less than 5 years * First degree relative with diabetes diagnosis * Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease) * Alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day * Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration * Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent
Treatments and study arms
The registry does not list a named intervention.
Primary outcomes
Beta-cell functionbefore and 7 days after rhGH administration
Insulin secretion rate in relationship to plasma glucose
Study locations
1 locations were listed when this page was built. The first 40 are shown.
University of Missouri School of Medicine🇺🇸 Columbia, Missouri, United States
Bettina MittendorferContact